common.study.topics.clinical

Experimental Treatment for High-Risk Pulmonary Nodules

common.study.values.description

Pembrolizumab in Treating Patients With High-Risk Pulmonary Nodules

This phase II trial studies how well pembrolizumab works in treating patients with high-risk pulmonary nodules. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the pre-malignant cells, and may inhibit the progression of pre-malignant cells into invasive cancer cells.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

No pharmaceutical medication involved common.study.methods.has-drugs-no
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Best Practice

Receive standard of care

Biological - Pembrolizumab

Given IV

Quality-of-Life Assessment

Ancillary studies

participant.views.study.view.additional

participant.views.study.view.scientific-title

Randomized Phase II of Immunotherapy With Pembrolizumab for the Prevention of Lung Cancer (IMPRINT-Lung)

common.study.values.clinical-trial-id

NCT03634241

participant.views.study.view.id

b826ge